Association of weight gain and metabolic syndrome in patients taking clozapine: An 8-year cohort study

Journal of Clinical Psychiatry

Volumn 72, Issue 6, 2011, Pages 751-756

  Bai, Ya Mei ^a,b   Lin, Chao Cheng ^c,d   Chen, Jen Yeu ^e   Chen, Tzu Ting ^e   Su, Tung Pine ^a,b   Chou, Pesus ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e YULI VETERANS HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CLOZAPINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX FACTORS; WEIGHT GAIN;

EID: 79959575968     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05402yel     Document Type: Article

References (40)

1. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32(2):289-297. doi:10.1038/sj.np.1301209 PubMed (Pubitemid 46106936)
2. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27. PubMed
3. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 (suppl 1):1-93 doi:10.2165/023210-2051901-01 PubMed. (Pubitemid 40677047)
4. Choi KM, Lee J, Lee KW, et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf). 2004;61(1):75-80. doi:10.1/j.1365-265.204.02063. x PubMed (Pubitemid 38951648)
5. Yatsuya H. Pathophysiologic mechanisms of obesity and related metabolic disorders: an epidemiologic study using questionnaire and serologic biomarkers. J Epidemiol. 2007;17(5):141-146. doi:10.218/jea.17.141 PubMed
6. Berrahmoune H, Herbeth B, Samara A, et al. Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way: the Stanislas study. Int J Obes (Lond). 2008;32(8):1279-1288. doi:10.1038/ijo.208.94 PubMed
7. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-809. PubMed
8. Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006;163(7):1273-1276. doi:10.176/api.ajp.163.7.1273 PubMed (Pubitemid 44464457)
9. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 2007;33(3):169-175. doi:10.1016/j.diabet. 207.01.03 PubMed (Pubitemid 46876639)
10. Avella J, Wetli CV, Wilson JC, et al. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am J Forensic Med Pathol. 2004;25(2):172-175. doi:10.1097/01.paf.0127391.8507.f4 PubMed (Pubitemid 38702547)
11. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111(9):716-723. doi:10.1016/S02-9343(01)010-2 PubMed (Pubitemid 34017524)
12. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22(7):841-852. doi:10.1592/phco.2.1.841.3629 PubMed (Pubitemid 34743435)
13. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345. doi:10.101/archpsyc.59.4.37 PubMed (Pubitemid 34275252)
14. Melkersson K, Hulting AL. [Antipsychotic drugs can affect hormone balance: weight gain, blood lipid disturbances and diabetes are important] [Article in Swedish]. Lakartidningen. 2001;98(48):5462-5464, 5467-5469. PubMed
15. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006;67(5):789-797. doi:10.408/JCP.v67n0513 PubMed (Pubitemid 43946186)
16. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19-28. doi:10.101/archpsyc.62.1.19 PubMed (Pubitemid 40096067)
17. Howes OD, Bhatnagar A, Gaughran FP, et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry. 2004;161(2):361-363. doi:10.176/api.ajp.161.2.361 PubMed (Pubitemid 38419289)
18. Lamberti JS, Costea GO, Olson D, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry. 2005;66(7):900-906. doi:10.408/JCP.v6n0713 PubMed (Pubitemid 41032832)
19. Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol. 2006;26(5):504-507. doi:10.1097/01.jcp.0237947.80764.d9 PubMed
20. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007;32(12):2561-2569. doi:10.1038/sj.np.1301392 PubMed (Pubitemid 350126844)
21. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272. doi:10.408/JCP.v65n0219 PubMed
22. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3):345-353. doi:10.176/api.ajp.208.08030383 PubMed
23. Mannucci E, Monami M, Cresci B, et al. National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. Diabetes Obes Metab. 2008;10(5):430-435. doi:10.1/j.1463-1326.207.0724.x PubMed
24. Chuang SY, Chen CH, Chou P. Prevalence of metabolic syndrome in a large health check-up population in Taiwan. J Chin Med Assoc. 2004;67(12):611-620. PubMed
25. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc. 2006;105(8):626-635. doi:10.1016/S0929-646(09) 60161-3 PubMed
26. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753-760. PubMed
27. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359. doi:10.101/jama.287.3.356 PubMed (Pubitemid 34251969)
28. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83(1):87-93. doi:10.1016/j.schres.205.12.85 PubMed
29. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. doi:10.1016/j.schres.205.07.014 PubMed (Pubitemid 41587460)
30. Patel A, Huang KC, Janus ED, et al. Is a single definition of the metabolic syndrome appropriate? a comparative study of the USA and Asia. Atherosclerosis. 2006;184(1):225-232. doi:10.1016/j.atherosclerosis.205.04.012 PubMed (Pubitemid 41721092)
31. Tirupati S, Chua LE. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry. 2007;15(6):470-473. doi:10.1080/10398560701636906 PubMed (Pubitemid 350120843)
32. Van Gaal LF. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol. 2006;16(suppl 3):S142-S148. doi:10.1016/j.euroneuro.206.06.05 PubMed (Pubitemid 44177766)
33. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66(4):504-514. doi:10.408/JCP.v6n0414 PubMed (Pubitemid 40593580)
34. Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother. 2000;34(7-8):865-867. doi:10.1345/aph.19327 PubMed (Pubitemid 30471268)
35. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes. 2005;54(5):1552-1558. doi:10.237/diabetes.54.5.152 PubMed (Pubitemid 40586689)
36. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54(3):862-871. doi:10.237/diabetes.54.3.862 PubMed (Pubitemid 40322092)
37. De Hert M, Hanssens L, van Winkel R, et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care. 2006;29(10):2329-2330. doi:10.237/dc-06-1393 PubMed (Pubitemid 44899881)
38. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull. 2007;33(3): 823-830. doi:10.1093/schbul/sbl037 PubMed (Pubitemid 47343707)
39. Nagamine T. Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia. Intern Med. 2008;47(3): 181-182. doi:10.2169/internalmedicine.47.057 PubMed (Pubitemid 351372634)
40. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28(2):132-137. (Pubitemid 351417117)